The approval of Hympavzi makes it the first treatment for both hemophilia A and B to be administered through a pre-filled pen ...

Hympavzi (marstacimab-hncq) for routine prophylaxis to prevent or reduce the frequency of bleeding episodes in adults and ...

HYMPAVZI is the first and only approved anti-tissue factor pathway inhibitor in the US for haemophilia A or B treatment.

The approval of Hympavzi Friday was a dose of good news for Pfizer, which is dealing with research setbacks and a challenge ...

Pfizer’s Hympavzi receives US FDA approval to treat adults and adolescents with haemophilia A or B without inhibitors: New York Monday, October 14, 2024, 18:00 Hrs [IST] Pfizer ...

Pfizer PFE announced that the FDA has approved its subcutaneously administered drug marstacimab for treating certain ...

The FDA has approved a new preventive treatment for people with certain types of hemophilia that can reduce bleeding episodes, sometimes down to just a few per year.

Inventiva will gain a new chairman following the deal as it presses ahead with a Phase III trial for its lead asset.

Daiichi Sankyo and AstraZeneca's ENHERTU has been conditionally approved by China's NMPA for a specific type of NSCLC.

One doctor spoke out warning that women may be getting misdiagnosed with a common condition when they may actually be ...

Cancer Research UK hailed the shift as the biggest improvement in cervical cancer treatment in more than 20 years ...

Reuters, the news and media division of Thomson Reuters, is the world’s largest multimedia news provider, reaching billions of people worldwide every day. Reuters provides business, financial ...